889 related articles for article (PubMed ID: 26200270)
21. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
23. [The diagnostic value of FDG coincidence imaging combined with serum tumor marker assays for pulmonary lesions].
Yang JG; Li CL; Gong M; Zou LF
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):683-5. PubMed ID: 17274375
[TBL] [Abstract][Full Text] [Related]
24. Folate-receptor-positive circulating tumor cells as an efficacious biomarker for the diagnosis of small pulmonary nodules.
Xue Y; Cong W; Xie S; Shu J; Feng G; Gao H
J Cancer Res Ther; 2018; 14(7):1620-1626. PubMed ID: 30589049
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
26. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
Li W; Li N; Kang X; Shi K
Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
[TBL] [Abstract][Full Text] [Related]
27. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
28. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
30. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
31. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
32. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
33. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer.
Yu Y; Chen Z; Dong J; Wei P; Hu R; Zhou C; Sun N; Luo M; Yang W; Yao R; Gao Y; Li J; Yang G; He W; He J
Transl Oncol; 2013 Dec; 6(6):697-702. PubMed ID: 24466372
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of serum tumor markers found in non-small cell lung cancer.
Hu Q; Xiao P; Li J; Yu P
J Cancer Res Ther; 2016; 12(1):117-20. PubMed ID: 27072222
[TBL] [Abstract][Full Text] [Related]
35. Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer.
Cheng H; He W; Yang J; Ye Q; Cheng L; Pan Y; Mao L; Chu X; Lu C; Li G; Qiu Y; He J
Cell Prolif; 2020 Sep; 53(9):e12880. PubMed ID: 32707596
[TBL] [Abstract][Full Text] [Related]
36. Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Chen L; Li Y; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820964222. PubMed ID: 33317398
[TBL] [Abstract][Full Text] [Related]
37. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
Zhou Q; Geng Q; Wang L; Huang J; Liao M; Li Y; Ding Z; Yang S; Zhao H; Shen Q; Pan C; Lou J; Lu S; Chen C; Luo Q
EBioMedicine; 2019 Mar; 41():236-243. PubMed ID: 30872130
[TBL] [Abstract][Full Text] [Related]
38. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
39. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
40. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]